J&J presses on with drug to prevent premature ejaculation

07/10/2007 | Wall Street Journal (free content), The

Other drugmakers have abandoned their search for a drug to prevent premature ejaculation, but Johnson & Johnson, whose first try was rejected by the FDA, is still in the hunt. The company intends to test its dapoxetine outside the U.S. and file for regulatory approval in Europe and Canada later this year. The FDA declined to approve it in 2005, questioning its medical benefit.

View Full Article in:

Wall Street Journal (free content), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Abbott
Santa Clara, CA
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA